tbuckley/cabot-search huggingface dataset:
Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation: Two-year Follow-up of the CASTLE-HTx Trial
Authors: Christian Sohns, Maximilian Moersdorf, Nassir F. Marrouche, Leonard Bergau, Angelika Costard-Jaeckle, Harry J.G.M. Crijns, Henrik Fox, Gerhard Hindricks, Nikolaos Dagres, Samuel Sossalla, Rene Schramm, Thomas Fink, Mustapha El Hamriti, Vanessa Sciacca, Maxim Didenko, Frank Konietschke, Volker Rudolph, Jan Gummert, Jan G.P. Tijssen, Philipp Sommer
Journal: Circulation (2024)
Acute Kidney Injury and High-Sensitivity Cardiac Troponin T Levels in the Emergency Department
Authors: Love Cyon, Erik Kadesjö, Gustaf Edgren, Andreas Roos
Journal: JAMA Network Open (2024)

The clinical implications of high-sensitivity cardiac troponin T (hs-cTnT) measurements in patients with acute kidney injury (AKI) in the emergency department (ED) are largely unknown.
Understanding Global Lived Experiences to Advance Oncology Care in Low- and Middle-Income Countries
Authors: Sudha Sivaram, Satish Gopal
Journal: JAMA Network Open (2024)

Hannah Simba, PhD; Miriam Mutebi, MD; Moses Galukande, MD; Yahya Mahamat-Saleh, PhD; Elom Aglago, PhD; Adamu Addissie, PhD; Lidya Genene Abebe, MS; Justina Onwuka, PhD; Grace Akinyi Odongo, PhD; Felix M. Onyije, PhD; Bernadette Chimera, MS; Melitah Motlhale, PhD; Neimar de Paula Silva, PhD; Desiree Malope, MS; Clement T. Narh, PhD; Elizabeth F. Msoka, MS; Joachim Schüz, PhD; Efua Prah, PhD; Valerie McCormack, PhD
Improving integrated perinatal care for women with hepatitis B in China
Authors: Yunshan Chen, Rong Fan, Lele Wang, Abraham (Nick) Morse, Huishu Liu
Journal: BMJ (2024)

<b>Huishu Liu and colleagues</b> argue that integrated care for women with hepatitis B in China needs improving, including better severity stratification, comprehensive counselling and education, seamless multidisciplinary care, and better referral
Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies
Authors: Tian Lan, Frank Tacke
Journal: Metabolism (2024)

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) continues to rise, making it the leading etiology of chronic liver diseases and a prime cause of liver-related mortality. MASLD can progress into steatohepatitis (termed MASH), fibrosis, cirrhosis, and ultimately cancer. MASLD is associated with increased risks of hepatocellular carcinoma (HCC) and also extrahepatic malignancies, which can develop in both cirrhotic and non-cirrhotic patients, emphasizing the importance of identifying patients with MASLD at risk of developing MASLD-associated malignancies. However, the optimal screening, diagnostic, and risk stratification strategies for patients with MASLD at risk of cancer are still under debate. Individuals with MASH-associated cirrhosis are recommended to undergo surveillance for HCC (e.g. by ultrasound and biomarkers) every six months. No specific screening approaches for MASLD-related malignancies in non-cirrhotic cases are established to date. The rapidly developing omics technologies, including genetics, metabolomics, and proteomics, show great potential for discovering non-invasive markers to fulfill this unmet need. This review provides an overview on the incidence and mortality of MASLD-associated malignancies, current strategies for HCC screening, surveillance and diagnosis in patients with MASLD, and the evolving role of omics technologies in the discovery of non-invasive markers for the prediction and risk stratification of MASLD-associated HCC.
Classical Monocytes Shuttling for Precise Delivery of Nanotherapeutics to Glioblastoma
Authors: Congwen Li, Congyi Niu, Lin Chen, Baichao Yu, Feifei Luo, Jingbo Qie, Hui Yang, Jiawen Qian, Yiwei Chu
Journal: Advanced Healthcare Materials (2024)

Glioblastoma (GBM) is the most aggressive brain tumor for which current therapies have limited efficacy. Immunosuppression and difficulties in accessing tumors with therapeutic agents are major obstacles for GBM treatments. Classical monocytes (CMs) possess the strongest infiltration among myeloid cells recruited into tumors during tumorigenesis. In this study, CMs are utilized to deliver the small-molecule CUDC-907 encapsulated in nanoparticles (907-NPs@CMs) for GBM therapy. Hitchhiking on CMs enables more 907-NPs to successfully penetrate the blood-brain barrier (BBB) and reach the interior of tumors. Results demonstrate that 907-NPs@CMs significantly improve the survival rates by suppressing tumor growth and reversing the immunosuppression of tumor microenvironment (TME). Furthermore, the high delivery efficiency of CMs reduces the amount of CUDC-907 required for treatments, reducing the physiological toxicity and off-target effects caused by high doses. 907-NPs@CMs is a safe and versatile therapeutic system that provides a platform for targeted drug delivery to tumors and the ability to treat GBM through a combination of chemotherapy and immunotherapy.
Tackling social and behavioural risk factors for cardiovascular diseases in Chinese women
Authors: Ruogu Meng, Wenxiu Wang, Tao Huang, Siyan Zhan
Journal: BMJ (2024)

Chinese women have benefited more than men from improvements in social determinants of health in decreasing the burden of cardiovascular diseases in recent decades; however, Chinese women, especially those in the younger generation, are facing new challenges, argue <b>Siyan Zhan and colleagues</b>
Children’s Sugary Drink Intake Has Increased Over 3 Decades
Authors: Samantha Anderer
Journal: JAMA (2024)

Children around the world consumed an average of 23% more sugar-sweetened beverages in 2018 than they did in 1990, new research published in The BMJ found. The population-based study examined data from the Global Dietary Database on people aged 3 years to 19 years from 185 countries.
More Reasons Not to Lower High Blood Pressure Early After Ischemic Stroke
Authors: Joanna M. Wardlaw
Journal: JAMA Network Open (2024)

Yufei Wei, MD, PhD; Xuewei Xie, MD, PhD; Yuesong Pan, PhD; Mengxing Wang, PhD; Aili Wang, MD, PhD; Dacheng Liu, MD, PhD; Zilin Zhao, MD; Ximing Nie, MD, PhD; Wanying Duan, MD, PhD; Xin Liu, MD, PhD; Zhe Zhang, MD, PhD; Jingyi Liu, MD, PhD; Lina Zheng, MD, PhD; Suwen Shen, MD; Chongke Zhong, MD, PhD; Tan Xu, MD, PhD; Yong Jiang, MD, PhD; Jing Jing, MD, PhD; Xia Meng, MD, PhD; Katherine Obst, MS; Chung-Shiuan Chen, MS; Hao Li, PhD; Xinyi Leng, MD, PhD; David Wang, MD, PhD; Yilong Wang, MD, PhD; Yonghong Zhang, MD, PhD; Jiang He, MD, PhD; Yongjun Wang, MD; Liping Liu, MD, PhD
Frailty in Medicare Advantage Beneficiaries and Traditional Medicare Beneficiaries
Authors: Sandra M. Shi, Brianne Olivieri-Mui, Chan Mi Park, Stephanie Sison, Ellen P. McCarthy, Dae H. Kim
Journal: JAMA Network Open (2024)

A growing proportion of the population is enrolling in Medicare Advantage (MA), which typically offers additional benefits compared with traditional Medicare (TM).
True Effect of Fludrocortisone for Septic Shock: Baseline Risk and Transitivity Concerns
Authors: Shodai Yoshihiro, Shunsuke Taito
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"True Effect of Fludrocortisone for Septic Shock: Baseline Risk and Transitivity Concerns." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation
Authors: Anne Doye, Paul Chaintreuil, Chantal Lagresle-Peyrou, Ludovic Batistic, Valentine Marion, Patrick Munro, Celine Loubatier, Rayana Chirara, Nataël Sorel, Boris Bessot, Pauline Bronnec, Julie Contenti, Johan Courjon, Valerie Giordanengo, Arnaud Jacquel, Pascal Barbry, Marie Couralet, Nathalie Aladjidi, Alain Fischer, Marina Cavazzana, Coralie Mallebranche, Orane Visvikis, Sven Kracker, Despina Moshous, Els Verhoeyen, Laurent Boyer
Journal: The Journal of Experimental Medicine (2024)

A growing number of patients presenting severe combined immunodeficiencies attributed to monoallelic RAC2 variants have been identified. The expression of the RHO GTPase RAC2 is restricted to the hematopoietic lineage. RAC2 variants have been described to cause immunodeficiencies associated with high frequency of infection, leukopenia, and autoinflammatory features. Here, we show that specific RAC2 activating mutations induce the NLRP3 inflammasome activation leading to the secretion of IL-1β and IL-18 from macrophages. This activation depends on the activation state of the RAC2 variant and is mediated by the downstream kinase PAK1. Inhibiting the RAC2-PAK1-NLRP3 inflammasome pathway might be considered as a potential treatment for these patients.
Structural Equality and Support Index in Early Childhood Education
Authors: Mirinda M. Morency, Arthur J. Reynolds, Marley Loveman-Brown, Rachel Kritzik, Suh-Ruu Ou
Journal: JAMA Network Open (2024)

Whether early childhood education is associated with a wide range of adult outcomes above and beyond individual- and family-level outcomes is unknown. As a consequence of improving educational and career success, it is postulated that participation in high quality, comprehensive programs can promote residence in more supportive community contexts in adulthood.
Cancer Care Terminology in African Languages
Authors: Hannah Simba, Miriam Mutebi, Moses Galukande, Yahya Mahamat-Saleh, Elom Aglago, Adamu Addissie, Lidya Genene Abebe, Justina Onwuka, Grace Akinyi Odongo, Felix M. Onyije, Bernadette Chimera, Melitah Motlhale, Neimar de Paula Silva, Desiree Malope, Clement T. Narh, Elizabeth F. Msoka, Joachim Schüz, Efua Prah, Valerie McCormack
Journal: JAMA Network Open (2024)

Effective communication between patients and health care teams is essential in the health care setting for delivering optimal cancer care and increasing cancer awareness. While the significance of communication in health care is widely acknowledged, the topic is largely understudied within African settings.
Large-scale hepatitis E virus genotype 3 outbreak on new caledonia island
Authors: Florence Abravanel, Clémence Vignon, Ambroise Mercier, Jean-Baptiste Gaumery, Antoine Biron, Clément Filisetti, Marie-Amélie Goujart, Julien Colot, Xavier Chamillard, Justine Demortier, Maxime Raz, Catherine Boutet, Laura Dupont, Sylvie Duval, Catherine Castric, Denise Desoutter, Anais Desoutter, Marjorie Verge, Clémentine De Smet, Sofia Demmou, Sébastien Lhomme, Ann-Claire Gourinat, Florence Nicot, Jacques Izopet
Journal: Hepatology (2024)

Several symptomatic cases of hepatitis E virus (HEV) infections were reported to the New Caledonia Island Public Health Service between August and December 2023. This prompted epidemiological and virological investigations to identify the source of infection.
Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
Authors: Lamiae Grimaldi, Tom Duchemin, Yann Hamon, Albert Buchard, Jacques Benichou, Lucien Abenhaim, Nathalie Costedoat-Chalumeau, Yola Moride
Journal: JAMA Network Open (2024)

Systemic lupus erythematosus (SLE) predisposes individuals to early cardiovascular (CV) events. While hydroxychloroquine is thought to mitigate CV risk factors, its protective role against CV events, particularly arterial ones, remains to be confirmed.
Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort
Authors: Liang En Wee, Jue Tao Lim, An Ting Tay, Calvin J. Chiew, Benjamin Ong, David Chien Boon Lye, Manjari Lahiri, Kelvin Bryan Tan
Journal: JAMA Network Open (2024)

Studies have reported increased risk of autoimmune sequelae after SARS-CoV-2 infection. However, risk may potentially be attenuated by milder Omicron (B.1.1.529) variant infection and availability of booster vaccination.
Automated Measurement of Cerebral Hemorrhagic Contusions and Outcomes After Traumatic Brain Injury in the TRACK-TBI Study
Authors: Samuel B. Snider, Nancy R. Temkin, Xiaoying Sun, Jacob L. Stubbs, Quinn J. Rademaker, Amy J. Markowitz, Eric S. Rosenthal, Ramon Diaz-Arrastia, Michael D. Fox, Geoffrey T. Manley, Sonia Jain, Brian L. Edlow
Journal: JAMA Network Open (2024)

Because withdrawal of life-sustaining therapy based on perceived poor prognosis is the most common cause of death after moderate or severe traumatic brain injury (TBI), the accuracy of clinical prognoses is directly associated with mortality. Although the location of brain injury is known to be important for determining recovery potential after TBI, the best available prognostic models, such as the International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT) score, do not currently incorporate brain injury location.
Rationale and design of <scp>RESILIENCE</scp>: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity
Authors: Andrea Moreno‐Arciniegas, Alberto García, Malte Kelm, Francesco D'Amore, María Gomes da Silva, Javier Sánchez‐González, Pedro L. Sánchez, Teresa López‐Fernández, Raul Córdoba, Riccardo Asteggiano, Vincent Camus, Jouke Smink, Antonio Ferreira, Marie J. Kersten, Natacha Bolaños, Noemi Escalera, Elsa Pacella, Sandra Gómez‐Talavera, Antonio Quesada, Xavier Rosselló, Borja Ibanez
Journal: European Journal of Heart Failure (2024)

Abstract Aims There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote ischaemic conditioning (RIC) has shown beneficial effects in preclinical models of AC. Methods REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs (RESILIENCE) is a multinational, prospective, phase II, double‐blind, sham‐controlled, randomized clinical trial that evaluates the efficacy and safety of RIC in lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles including anthracyclines and with ≥1 AC‐associated risk factors will be randomized to weekly RIC or sham throughout the chemotherapy period. Patients will undergo three multiparametric cardiac magnetic resonance (CMR) studies, at baseline, after the third cycle (intermediate CMR), and 2 months after the end of chemotherapy. Thereafter, patients will be followed up for clinical events over an anticipated median of ≥24 months. The primary endpoint is the absolute change from baseline in CMR‐based left ventricular ejection fraction (LVEF). The main secondary outcome is the incidence of AC events, defined as (1) a drop in CMR‐based LVEF of ≥10 absolute points, or (2) a drop in CMR‐based LVEF of ≥5 and &lt;10 absolute points to a value &lt;50%. Intermediate CMR will test the ability of T2 mapping to predict AC versus classical markers (left ventricular strain and cardiac injury biomarkers). A novel CMR sequence allowing ultrafast cine acquisition will be validated in this vulnerable population. Conclusions The RESILIENCE trial will test RIC (a novel non‐invasive intervention to prevent AC) in a cohort of high‐risk patients. The trial will also test candidate markers for their capacity to predict AC and will validate a novel CMR sequence reducing acquisition time in a vulnerable population.
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease
Authors: Katja Vu Bartholdy, Niklas Dyrby Johansen, Kira Hyldekær Janstrup, Daniel Modin, Joshua Nealon, Sandrine Samson, Matthew M Loiacono, Rebecca Harris, Carsten Schade Larsen, Anne Marie Reimer Jensen, Nino Emanuel Landler, Brian L Claggett, Scott D Solomon, Martin J Landray, Gunnar H Gislason, Ditte Hansen, Lars Køber, Pradeesh Sivapalan, Lasse Skafte Vestergaard, Jens Ulrik Stæhr Jensen, Tor Biering-Sørensen
Journal: Journal of the American College of Cardiology (2024)
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
Authors: Alyssa M Pereslete, Melissa E Hughes, Alyssa R Martin, Janet Files, Kyleen Nguyen, Lauren Buckley, Ashka Patel, Abigail Moore, Eric P Winer, Deborah Dillon, Tianyu Li, Sara M Tolaney, Nancy U Lin, Sarah L Sammons
Journal: Neuro-Oncology (2024)

Abstract Background There are limited data regarding HER2-low expression dynamics between matched primary tumors and brain metastases (BrMs) in breast cancer. HER2-low expression has emerged as a new therapeutic biomarker for highly active antibody-drug conjugates with emerging intracranial activity. Methods Patients with metastatic breast cancer and BrMs seen at an NCI-designated center between 2003 and 2023 were identified. HER2 expression was defined as HER2-positive (3+, 2+/ISH amplified), HER2-low (1+, 2+/ISH negative), or HER2–0 by ASCO-CAP guidelines. Estrogen receptor (ER) status was defined as ER ≥1%. Multivariate survival analyses by Cox proportional hazard models were determined from the time of BrM resection to death or last follow-up between the 3 subtypes, controlling for ER and age. Results Among 197 matched primary and resected BrMs, 81% exhibited HER2 expression in the brain: 61% HER2-positive, 20% HER2-low, and 19% HER2–0. Concordance was high in HER2-positive primary tumors with 100% retaining HER2 expression (97% retained HER2-positive expression and 2.7% switched to HER2-low). HER2–0 primaries frequently showed HER2 gain in BrMs to HER2-low (35%) or HER2-positive (5.4%) status. Among 48 HER2-low primary tumors, 52% were discordant for HER2 status in the brain with 21% testing HER2-positive and 31% testing HER2–0. In adjusted analyses, patients with HER2-positive BrMs had significantly lower death risk than patients with HER2-low BrMs (HR = 0.41, P = .0006); no difference was observed between HER2–0 and HER2-low. Conclusions In this retrospective analysis, HER2 expression is common in breast cancer BrMs, emphasizing the need for improved, noninvasive diagnostics. Patients with HER2-low and HER2–0 BrMs face inferior survival, presenting an unmet clinical need.
Ecosystem synchrony: an emerging property to elucidate ecosystem responses to global change
Authors: Chloé Vagnon, Julian D Olden, Stéphanie Boulêtreau, Rosalie Bruel, Mathieu Chevalier, Flavien Garcia, Gordon Holtgrieve, Michelle Jackson, Elisa Thebault, Pablo A Tedesco, Julien Cucherousset
Journal: Trends in Ecology & Evolution (2024)
A biomimetic upconversion nanoreactors for near-infrared driven H2 release to inhibit tauopathy in Alzheimer's disease therapy
Authors: Qin Zhang, Chuanqi Li, Bohan Yin, Jiaxiang Yan, Yutian Gu, Yingying Huang, Jiareng Chen, Xinyue Lao, Jianhua Hao, Changqing Yi, Yi Zhou, James Chung Wai Cheung, Siu Hong Dexter Wong, Mo Yang
Journal: Bioactive Materials (2024)

Abnormal hyperphosphorylation of tau protein is a principal pathological hallmark in the onset of neurodegenerative disorders, such as Alzheimer's disease (AD), which can be induced by an excess of reactive oxygen species (ROS). As an antioxidant, hydrogen gas (H
Efficacy and safety of low‐dose digoxin in patients with heart failure. Rationale and design of the DECISION trial
Authors: Dirk J. van Veldhuisen, Michiel Rienstra, Arend Mosterd, A. Marco Alings, Antoinette D.J. van Asselt, Marcel L Bouvy, Jan G.P. Tijssen, Jeroen Schaap, Ernst E. van der Wall, Adriaan A. Voors, Eva M. Boorsma, Dirk J.A. Lok, Harry J.G.M. Crijns, Astrid Schut, Marlene A.T. Vijver, Geert H.D. Voordes, Agaath H. de Vos, Ester L. Maas‐Soer, Nicoline W. Smit, Daan J. Touw, Michelle Samuel, Peter van der Meer
Journal: European Journal of Heart Failure (2024)

Digoxin is the oldest drug in cardiovascular (CV) medicine, and one trial conducted >25 years ago showed a reduction in heart failure (HF) hospitalizations but no effect on mortality. However, later studies suggested that the dose of digoxin used in that trial (and other studies) may have been too high. The DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands) trial will examine the efficacy and safety of low-dose digoxin in HF patients with reduced or mildly reduced left ventricular ejection fraction (LVEF) with a background of contemporary HF treatment.
Inhibition of myeloperoxidase to treat left ventricular dysfunction in non‐ischaemic cardiomyopathy
Authors: Simon Geissen, Simon Braumann, Joana Adler, Felix Sebastian Nettersheim, Dennis Mehrkens, Alexander Hof, Henning Guthoff, Philipp von Stein, Sven Witkowski, Norbert Gerdes, Frederik Tellkamp, Marcus Krüger, Lea Isermann, Aleksandra Trifunovic, Alexander C. Bunck, Martin Mollenhauer, Holger Winkels, Matti Adam, Anna Klinke, Gregor Buch, Vincent ten Cate, Martin Hellmich, Malte Kelm, Volker Rudolph, Philipp S. Wild, Stephan Rosenkranz, Stephan Baldus
Journal: European Journal of Heart Failure (2024)

Non-ischaemic cardiomyopathy (NICMP), an incurable disease terminating in systolic heart failure (heart failure with reduced ejection fraction [HFrEF]), causes immune activation, however anti-inflammatory treatment strategies so far have failed to alter the course of this disease. Myeloperoxidase (MPO), the principal enzyme in neutrophils, has cytotoxic, pro-fibrotic and nitric oxide oxidizing effects. Whether MPO inhibition ameliorates the phenotype in NICMP remains elusive.
Arrhythmic Risk Stratification by Cardiovascular Magnetic Resonance Imaging in Patients With Nonischemic Cardiomyopathy
Authors: Daniel J Hammersley, Abbasin Zegard, Emmanuel Androulakis, Richard E Jones, Osita Okafor, Suzan Hatipoglu, Lukas Mach, Amrit S Lota, Zohya Khalique, Antonio de Marvao, Ankur Gulati, Resham Baruah, Kaushik Guha, James S Ware, Upasana Tayal, Dudley J Pennell, Brian P Halliday, Tian Qiu, Sanjay K Prasad, Francisco Leyva
Journal: Journal of the American College of Cardiology (2024)

Myocardial fibrosis (MF) forms part of the arrhythmic substrate for ventricular arrhythmias (VAs).
Dynamic and Static Workout of In Vitro Skeletal Muscle Tissue through a Weight Training Device
Authors: Byeongwook Jo, Kentaro Motoi, Yuya Morimoto, Shoji Takeuchi
Journal: Advanced Healthcare Materials (2024)

Enhancing muscle strength through workouts is a key factor in improving physical activity and maintaining metabolic profiles. The controversial results concerning the impacts of weight training often arise from clinical experiments that require controlled experimental conditions. In this study, a weight training system for a muscle development model is presented, which is capable of performing weight training motions with adjustable weight loads. Through the implementation of cultured skeletal muscle tissue with floating structures and a flexible ribbon, both isotonic (dynamic change in muscle length) and isometric (static in muscle length) exercises can be performed without the deflection of the tissue. Quantitative analysis of contraction force, changes in metabolic processes, and muscle morphology under different weight training conditions demonstrates the effectiveness of the proposed system. Our proposed system holds potential for establishing effective muscle development and for further applications in rehabilitation training methods.
Global burden of vaccine‐associated angioedema and their related vaccines, 1967–2023: Findings from the global pharmacovigilance database
Authors: Yi Deun Jeong, Kyeongmin Lee, Jaeyu Park, Jinseok Lee, Jiseung Kang, Seung Geun Yeo, Lee Smith, Hayeon Lee, Dong Keon Yon
Journal: Allergy (2024)

The data are available upon request. Study protocol and statistical code: Available from DKY ([email protected]). Dataset: Available from the Uppsala Monitoring Center or WHO through a data use agreement. Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.